Spots Global Cancer Trial Database for inotuzumab ozogamicin
Every month we try and update this database with for inotuzumab ozogamicin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL | NCT03460522 | Precursor Cell ... | Inotuzumab ozog... | 56 Years - 74 Years | Goethe University | |
| InO - A Retrospective Study of UK Patients With Leukaemia | NCT04456959 | Precursor Cell ... | Inotuzumab Ozog... | 18 Years - | Pfizer | |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | NCT02981628 | Recurrent B Acu... Recurrent B Lym... Refractory B Ac... Refractory B Ly... | Asparaginase Er... Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cyclophosphamid... Cytarabine Diagnostic Imag... Inotuzumab Ozog... Leucovorin Calc... Lumbar Puncture Methotrexate Pegaspargase Vincristine | 1 Year - 21 Years | Children's Oncology Group | |
| Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | NCT03488225 | Acute Lymphobla... B Acute Lymphob... B Acute Lymphob... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 16 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | NCT02311998 | B Acute Lymphob... Blast Phase Chr... Blasts More Tha... CD22 Positive Philadelphia Ch... Recurrent Chron... Refractory Chro... | Bosutinib Inotuzumab Ozog... | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | NCT03488225 | Acute Lymphobla... B Acute Lymphob... B Acute Lymphob... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 16 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | NCT02311998 | B Acute Lymphob... Blast Phase Chr... Blasts More Tha... CD22 Positive Philadelphia Ch... Recurrent Chron... Refractory Chro... | Bosutinib Inotuzumab Ozog... | 18 Years - | M.D. Anderson Cancer Center | |
| Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | NCT00299494 | B-Cell Lymphoma | inotuzumab ozog... inotuzumab ozog... inotuzumab ozog... Rituximab | 18 Years - | Pfizer | |
| Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | NCT03913559 | Acute Lymphobla... | Inotuzumab ozog... Methotrexate Hydrocortisone Cytarabine Diphenhydramine Acetaminophen Methylprednisol... | - 21 Years | St. Jude Children's Research Hospital | |
| A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | NCT01564784 | Acute Lymphobla... | inotuzumab ozog... FLAG (fludarabi... HIDAC (high dos... cytarabine and ... | 18 Years - | Pfizer | |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | NCT05303792 | B Acute Lymphob... B Lymphoblastic... | Cyclophosphamid... Vincristine Dexamethasone Inotuzumab Ozog... Methotrexate Cytarabine Methylprednisol... Rituximab Prednisone Mercaptopurine Doxorubicin | 50 Years - | Alliance for Clinical Trials in Oncology | |
| Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy | NCT05456698 | Acute Lymphocyt... | Inotuzumab ozog... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | NCT05748171 | ACUTE LYMPHOBLA... | Inotuzumab ozog... ALLR3 | 1 Year - 17 Years | Pfizer | |
| Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | NCT00867087 | Lymphoma, B-Cel... | inotuzumab ozog... rituximab | 18 Years - | Pfizer | |
| Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | NCT05303792 | B Acute Lymphob... B Lymphoblastic... | Cyclophosphamid... Vincristine Dexamethasone Inotuzumab Ozog... Methotrexate Cytarabine Methylprednisol... Rituximab Prednisone Mercaptopurine Doxorubicin | 50 Years - | Alliance for Clinical Trials in Oncology | |
| Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia | NCT06427330 | Acute Lymphoid ... | Inotuzumab ozog... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | NCT03150693 | B Acute Lymphob... | Allopurinol Cytarabine Daunorubicin Hy... Vincristine Sul... Dexamethasone Pegylated L-Asp... Methotrexate Bone Marrow Asp... Cyclophosphamid... Mercaptopurine Rituximab Doxorubicin Thioguanine Inotuzumab Ozog... Laboratory Biom... | 18 Years - 39 Years | Alliance for Clinical Trials in Oncology | |
| Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | NCT03913559 | Acute Lymphobla... | Inotuzumab ozog... Methotrexate Hydrocortisone Cytarabine Diphenhydramine Acetaminophen Methylprednisol... | - 21 Years | St. Jude Children's Research Hospital | |
| Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | NCT00867087 | Lymphoma, B-Cel... | inotuzumab ozog... rituximab | 18 Years - | Pfizer | |
| Venetoclax Plus Inotuzumab for B-ALL | NCT05016947 | B-cell Acute Ly... B-Cell Lymphoma ALL | Venetoclax Dexamethasone Inotuzumab Ozog... | 18 Years - | Dana-Farber Cancer Institute | |
| Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | NCT00867087 | Lymphoma, B-Cel... | inotuzumab ozog... rituximab | 18 Years - | Pfizer | |
| Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease | NCT03441061 | Acute Lymphobla... B Acute Lymphob... Recurrent B Acu... | Inotuzumab Ozog... | 18 Years - | M.D. Anderson Cancer Center | |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | NCT03959085 | B Acute Lymphob... B Lymphoblastic... Central Nervous... Mixed Phenotype... Testicular Leuk... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bone Scan Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Leucovorin Calc... Magnetic Resona... Mercaptopurine Methotrexate Pegaspargase Positron Emissi... Prednisolone Questionnaire A... Radiation Thera... Radiation Thera... Thioguanine Vincristine Sul... | 1 Year - 25 Years | Children's Oncology Group | |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | NCT06087419 | Acute Lymphobla... | chidamide Venetoclax Oral... Inotuzumab Ozog... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia | NCT03094611 | CD22 Positive Recurrent Acute... Refractory Acut... | Inotuzumab Ozog... | 12 Years - | M.D. Anderson Cancer Center | |
| Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL | NCT03962465 | B-cell Acute Ly... | Inotuzumab ozog... Prednisone Pill Daunorubicin Vincristine Cytarabine Methotrexate Pegaspargase | 16 Years - 60 Years | University of Virginia | |
| Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma | NCT01535989 | B-cell Lymphoma... | Inotuzumab Ozog... Temsirolimus | 18 Years - | Oncology Institute of Southern Switzerland | |
| Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL | NCT03460522 | Precursor Cell ... | Inotuzumab ozog... | 56 Years - 74 Years | Goethe University | |
| S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia | NCT01925131 | Acute Leukemias... B-cell Adult Ac... Philadelphia Ch... Recurrent Adult... Recurrent Adult... | cyclophosphamid... vincristine sul... prednisone inotuzumab ozog... laboratory biom... | 18 Years - | SWOG Cancer Research Network | |
| A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT05687032 | Acute Lymphobla... | inotuzumab ozog... | 18 Years - | Pfizer | |
| Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | NCT03104491 | Acute Lymphocyt... | Inotuzumab Ozog... | 16 Years - 75 Years | Case Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
